Full Title
COMparative Prospective Assessment through Clinically Integrated Randomized Trials Evaluating Intravesical Treatments: The COMPARE IT Trial (Pragmatic)Purpose
Researchers are comparing different treatments for non-muscle invasive bladder cancer (NMIBC). The people in this study have NMIBC that keeps growing after treatment with an immunotherapy called Bacillus Calmette-Guerin (BCG). They do not want surgery to remove the bladder (radical cystectomy).
The standard treatments for this kind of NMIBC include:
- Nadofaragene firadenovec
- Gemcitabine with or without docetaxel
- Mitomycin
- Re-treatment with BCG
- Pembrolizumab immunotherapy
It is often difficult to know which of these treatments is best for any one particular person. If you join this study, you will receive one of these standard treatments as part of your care. Researchers will collect information about your outcomes so we can compare these standard treatments between patients.
Who Can Join
To join this study, there are a few conditions. You must:
- Have NMIBC that keeps growing after BCG treatment.
- Not be planning to have radical cystectomy.
- Not have previously been treated with nadofaragene firadenovec.
- Be age 21 or older.
Contact
For more information or to see if you can join this study, please call Dr. Eugene Pietzak’s office at 646-422-4781.